Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

NCT01042795 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Study closed due to poor accrual

Conditions

Urothelial Carcinoma
Bladder Cancer

Interventions

DRUG: Sunitinib

Sponsor

University of Michigan

Collaborators

[object Object]